Rankia Colombia Rankia Argentina Rankia Brasil Rankia Chile Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
14.005 / 16.979
#112033

Re: Farmas USA

Pintaza! 17$ estoy viendo!

Los números son muy buenos, el pipeline muy extenso, el potencial también y el cash en 750 mill. Me parece muy buena empresa la verdad.

Exel

#112034

Re: Farmas USA

APPL bien, -3% jajaja son la leche!

Q4 GAAP EPS of $2.91 beats by $0.13.

Revenue of $62.9B (+19.6% Y/Y) beats by $1.44B. Voy a ver que causa dan

#112035

Re: Farmas USA

TSRO

Tras resultados sube a 34. En el día 18%.

Supongo serán buenos. El caso es que suba.

 

#112036

Re: Farmas USA

Nada el shipment del iphone...por que los mac sube..algo sinsentido.

Mejores ventas, mejores margenes, eps, growth... Me suena a intercambios de cromos entre grandes para haber que cazan mañana y meterle un +10% y a maximos (casi me juego una cerveza a 233 en dias).

El SPY $ariiba abajo...pero lo que mas me gusta es que el Vix perdio ya los 20...puede irse abajo rapido y arriba su asociado.

#112037

Re: Farmas USA

Je,je,je , el payaso amarillo es el principal shortista aqui y Clytrade con el .

2 DE NOV.REGALITO DE CAMAPANA ELECTORAL EL PROXIMO MARTES 6

-------------------

Equities roar on U.S.-China trade developments  Nov. 2, 2018 2:56 AM ET|By:  Yoel Minkoff, SA News Editor 

Stocks across the globe are advancing rapidly on positive trade developments between the U.S and China.

President Trump has asked officials in his administration to start drafting terms of a trade deal with Beijing, sources  told Bloomberg, which reported that multiple agencies are involved in the effort.

Hopes are for reaching an agreement with Chinese President Xi Jinping later this month at the G20 summit in Argentina.

Asia: Nikkei +2.6%; Hang Seng +3.6%; Shanghai +2.5%; Sensex +1.8%.  European futures: FTSE 100 +1.2%.

U.S. futures: Dow +0.9%; S&P +0.9%; Nasdaq +0.8%..

https://seekingalpha.com/news/3404577-equities-roar-u-s-china-trade-developments?app=1#email_link

Los futuros europeos, en verde tras la esperanza de un acuerdo EE.UU.-China

La Bolsa de Seúl sube un 3,53 % al cierre hasta 2.096 puntos
Por Investing.com - Hace 9 minutos

La Bolsa de Tokio cierra con una subida del 2,56 % hasta los 22.243,66 puntosPor EFE - Hace 23 minutos

https://es.investing.com/news/stock-market-news

#112038

Re: Farmas USA

Leches! Las Xiaomi subiendo un 9%. Seguimos con los días de la rúcula ;-)

#112039

Re: Farmas USA

Si, lo puse por Pulso... Hasta las mid term pump&dump Presidential 😁😁😁
Luego a partir de la segunda semana para calentarse el G20 pues se acaba el Mundo jj

#112040

Re: Farmas USA

JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action

Nov. 2, 2018 7:59 AM ET|By:  Douglas W. House, SA News Editor 

Abiomed (NASDAQ: ABMD) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket.

Emergent BioSolutions (NYSE: EBS) upgraded to Buy with a $75 (17% upside) price target at Goldman Sachs after yesterday's Q3 report.

Adverum Biotechnologies (NASDAQ: ADVM) downgraded to Market Perform at Raymond James after bailing on gene therapy for A1AT deficiency. Shares down 31% premarket.

Amarin (NASDAQ: AMRN) downgraded to Neutral with a $28 (24% upside) price target after yesterday's Q3 report. Shares down 1% premarket.

Allscripts Healthcare Solutions (NASDAQ: MDRX) downgraded to Neutral with a $12 (flat) price target at Cantor Fitzgerald after yesterday's Q3 miss. Also downgraded to Neutral with a $12 price target at JPMorgan. Shares down 18% premarket.

Intellia Therapeutics (NASDAQ: NTLA) downgraded to Neutral at Wedbush after its Q3 miss. Shares down 4% premarket.

Puma Biotechnology (NYSE: PBYI) downgraded to Underweight with a $23 (40% downside risk) at JPMorgan and downgraded to Underweight with a $29 price target at Barclays after yesterday's Q3 report that included only modest sequential growth for Nerlynx. Shares down 35% premarket.

https://seekingalpha.com/news/3404677-jpmorgan-barclays-bearish-puma-premarket-healthcare-analyst-action?app=1#email_link

Brokers destacados